Milestone Pharmaceuticals (MIST) Projected to Post Quarterly Earnings on Tuesday

Milestone Pharmaceuticals (NASDAQ:MIST) will likely be issuing its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 8:00 AM ET.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). On average, analysts expect Milestone Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Milestone Pharmaceuticals Trading Up 0.3%

Shares of NASDAQ MIST traded up $0.01 during midday trading on Tuesday, reaching $1.86. The company had a trading volume of 252,162 shares, compared to its average volume of 1,609,029. Milestone Pharmaceuticals has a 1 year low of $0.63 and a 1 year high of $2.75. The business’s 50-day simple moving average is $1.93 and its 200 day simple moving average is $1.70. The stock has a market cap of $157.66 million, a P/E ratio of -2.21 and a beta of 0.54.

Analysts Set New Price Targets

MIST has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Wednesday, October 8th. Wells Fargo & Company assumed coverage on Milestone Pharmaceuticals in a research report on Thursday, September 11th. They issued an “overweight” rating and a $4.00 target price on the stock. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $4.50.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A hedge fund recently raised its stake in Milestone Pharmaceuticals stock. Raymond James Financial Inc. lifted its position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 30.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,235 shares of the company’s stock after purchasing an additional 10,000 shares during the period. Raymond James Financial Inc. owned about 0.08% of Milestone Pharmaceuticals worth $84,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 86.18% of the stock is currently owned by institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.